Summary
The pharmacokinetics of bismuth subcitrate were studied in plasma and urine under conditions of single and multiple dosing (28–56 days) using atomic absorption technique.
Single dose plasma pharmacokinetics showed peak concentrations of 5.5–57.5 µg·l−1 (mean=24.7 µg·l−1), reached between 30 and 60 min post dosing with an apparent biphasic elimination pattern. Multiple dose studies showed a continuing rise in plasma concentration and urine excretion rate reaching apparent steady-state levels over 7–29 days (mean=18 days). Washout studies in 6 individuals reciprocated accumulation. Maximum equilibrated plasma levels of 7.6–58.3 µg·l−1 (mean=38.3 µg·l−1) were well below those associated with encephalopathy. The half-life of bismuth elimination was 20.7 days.
Present patterns of intermittent dosing with bismuth are unlikely to be associated with bismuth accumulation despite slow accumulation and elimination.
This is a preview of subscription content, log in via an institution to check access.
References
McLean AJ, Harrison PM, Ioannides-Demos L, Bryne AJ, McCarthy P, Dudley FJ (1985) The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust NZ J Med 15: 367–374
Miller JP, Faragher EB (1986) Initial treatment really does influence relapse in duodenal ulcer. Br Med J 293: 1117–1118
Lee FI, Samloff IM, Hardman M (1985) Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcer. Lancet 2: 1299–1302
Martin DF, Hollanders D, May SJ, Ravenscroft MM, Tweddle DEF, Miller JP (1981) Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuth. Lancet 1: 7–10
McLean AJ, Harcourt DM, McNeil JJ (1988) Relapse rate as a major determinant of drug selection in peptic ulcer disease. Drugs 35: 329–333
McLean AJ, Harcourt DM, McCarthy PG, Dudley FJ, McNeil JJ (1987) Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing. Med J Aust 146: 431–438
McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 293: 645–649
Supino-Viterbo V, Sicard C, Risvegliato M, Rancurel G, Buge A (1977) Toxic encephalopathy due to ingestion of bismuth salts: Clinical and EEG studies of 45 patients. J Neurol Neurosurg Psychiatry 40: 748–752
Czerwinski AW, Earl Ginn H (1964) Bismuth nephrotoxicity. Am J Med 37: 960–974
Gaucher A, Netter P, Faure G (1979) Bismuth-induced osteoarthropathies. Med J Aust 24: 129–130
Loiseau P, Henry P, Jallon P, Legroux M (1976) Encephalopathies myocloniques iatrogènes aux sels de bismuth. J Neurol Sci 27: 133–143
Boiteau HL, Cler JM, Mathe JF, Delobel R, Feve JR (1976) Relations entre l'evolution des encephalopathies bismuthiques et les taux de bismuth dans le sang et dans les urines. Eur J Toxicol 9: 233–239
Monseau G, Struelens M, Roland M (1976) Bismuth encephalopathy. Acta Neurol Belg 76: 301–308
Froomes PRA, Wan AT, Harrison PM, McLean AJ (1988) Improved assay for bismuth in biological samples by atomic absorption spectrophotometry with hydride generation. Clin Chem 34: 382–384
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Lea & Febiger, Philadelphia
Pieri F, Wegmann R (1981) Etude pharmacocinetique du205/206Bi-citrate chez le rat. Repartition compartimentale. Cell Mol Biol 27: 57–60
Lee SP (1981) Studies on the absorption and excretion of tripotassium dicitrato bismuthate in man. Res Comm Chem Pathol Pharmacol 34: 359–364
Bianchi Porro G, Lazzaroni M, De Nicole C, Pace F (1984) Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine. Lancet 2: 698
Author information
Authors and Affiliations
Additional information
Presented in part to 89th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, California, March 1988
Rights and permissions
About this article
Cite this article
Froomes, P.R.A., Wan, A.T., Keech, A.C. et al. Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate. Eur J Clin Pharmacol 37, 533–536 (1989). https://doi.org/10.1007/BF00558139
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558139